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SYNOPSIS
Care bundles were defined for first response and refractory PPH. Implementation 
strategies, refractory PPH definition, and effectiveness of intrauterine balloon tamponade 
require further consultation. 
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ABSTRACT
Objective: To systematically develop evidence-based bundles for care of postpartum 
hemorrhage (PPH).
Methods: An international technical consultation was conducted in 2017 to develop draft 
bundles of clinical interventions for PPH taken from the WHO’s 2012 and 2017 PPH 
recommendations and based on the validated “GRADE Evidence-to-Decision” 
framework. Twenty-three global maternal-health experts participated in the development 
process, which was informed by a systematic literature search on bundle definitions, 
designs, and implementation experiences. Over a 6-month period, the expert panel met 
online and via teleconferences, culminating in a 2-day in-person meeting.
Results: The consultation led to the definition of two care bundles for facility 
implementation. The “first response to PPH bundle” comprises uterotonics, isotonic 
crystalloids, tranexamic acid, and uterine massage. The “response to refractory PPH 
bundle” comprises compressive measures (aortic or bimanual uterine compression), the 
non-pneumatic antishock garment, and intrauterine balloon tamponade (IBT). Advocacy, 
training, teamwork, communication, and use of best clinical practices were defined as 
PPH bundle supporting elements. 
Conclusion: For the first response bundle, further research should assess its feasibility, 
acceptability, and effectiveness; and identify optimal implementation strategies. For the 
response to refractory bundle, further research should address pending controversies, 
including the operational definition of refractory PPH and effectiveness of IBT devices.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
1 INTRODUCTION
Postpartum hemorrhage (PPH) occurs in approximately 5% of all live births and, despite 
concentrated efforts, remains a leading cause of maternal morbidity and mortality [1]. 
Because most PPH-related deaths are preventable through the implementation of 
effective interventions, the recent shift from home births to facility births across low- and 
middle-income countries (LMIC) raises new opportunities for saving women’s lives [2, 3]. 
Unfortunately, inconsistent and/or delayed use of effective interventions for prevention 
and treatment of PPH, in addition to other systemic problems in health services (e.g., lack 
of blood banks, inadequate staffing), has led to continued unacceptable rates of 
hemorrhage-related maternal deaths [4-6].
Care bundles have been associated with improved patient outcomes when adherence is 
high [7-9]. The concept of care bundles is similar to that of packages and checklists, 
which have been used by healthcare providers for decades with a similar goal of 
standardizing and expediting care (Supplementary Box S1). Care bundles may include 
behaviors, such as the widely used “ABCs” designed to help practitioners remember the 
sequence for resuscitation, or a number of interventions packaged together, such as the 
“Active Management of the Third Stage of Labor” (AMTSL) package used to prevent 
PPH. 
In 2001, the Institute for Healthcare Improvement (IHI) developed a formal approach to 
bundling care to increase the quality and efficiency of care delivery [10]. The IHI defined 
bundles as “small sets of evidence-based interventions for a defined patient population 
and care setting that, when implemented together, result in significantly better outcomes 
than when implemented individually” [10]. The “bundles” approach was designed to 
increase uptake and compliance to recommended interventions [10]. Care bundles differ 
from other care packages in that compliance is achieved only when all the bundled 
interventions are completed and recorded. Thus, compliance for the bundle as a whole 
implies higher rates of compliance for its individual elements [10]. Teamwork, 
communication, and cooperation are emphasized, because these health systems’ 
processes are required for quality and sustainability [10].A
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In 2012, WHO published its “Recommendations for the Prevention and Treatment of 
Postpartum Haemorrhage” to provide evidence-informed clinical care recommendations 
for hemorrhage due to uterine atony [11]. However, adherence to these 
recommendations remains a challenge [6]. The bundle approach has been proposed as a 
potential solution to suboptimal adherence to PPH guidelines [4]. Healthcare bundles 
have been proposed for maternal conditions including placenta previa, elective induction, 
labor augmentation, vacuum delivery, maternal sepsis, and obstetric anal sphincter injury 
[10, 12, 13], but evidence of their success or failure is lacking. Although many current 
patient safety programs target PPH [3, 5, 14-16], there are no patient care bundles for 
PPH as defined by the IHI.
In early 2017, WHO decided to explore whether bundling current WHO-recommended 
evidenced-based interventions for PPH due to uterine atony might accelerate adoption 
and adherence to PPH guidelines. The aim of the present study was to describe the first 
steps toward that goal: the adoption of a bundle definition, the PPH intervention selection 
criteria, and the process for the development of two PPH care bundles. 
2 MATERIALS AND METHODS
The consultation for the development of care bundles for PPH was carried out among 
international maternal health experts between October 2, 2017 and December 8, 2017. 
Completion of the online surveys and attendance at the in-person meeting implied 
participant consent. The consultation did not require review by an institutional review 
board.
Postpartum hemorrhage was defined as bleeding that a skilled birth attendant (SBA) 
feels is excessive and worrisome for this exercise [17]. In addition, in the absence of an 
accepted definition of refractory PPH, it was defined as bleeding that is unresponsive to 
initial treatment and that triggers an additional set of interventions.
Development of the bundles was undertaken by a panel of experts with geographic and 
professional diversity (Supplementary File S1). The PPH bundles were developed first by 
conducting a systematic literature search to define care bundles and their essential A
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characteristics in general; and then by identifying criteria to guide the selection of 
interventions for the PPH bundles. The selection of the interventions to be included in the 
bundles was made through technical consultations. Figure 1 outlines the process 
followed for bundle development. 
The literature search was conducted by using PubMed, Medline, Cochrane Library, 
LILACS, WHO, PAHO, and Google to identify peer-reviewed studies and grey literature 
(Supplementary File S2). Articles were included if they addressed the concept, 
development, and scientific evidence of patient care bundles in any field of medicine, with 
special attention to maternal healthcare and PPH bundles.
Regarding PPH bundles, the broad literature search initially looked at care bundles based 
on WHO recommendations and others. The interventions considered for inclusion in the 
PPH bundles were those specified in the 2012 WHO recommendations for hemorrhage 
due to uterine atony and the WHO 2017 update on tranexamic acid (TXA). To guide the 
selection of interventions, 11 criteria were selected from the validated and WHO-adopted 
“GRADE Evidence to Decision” framework [18] and 1 from the care bundle literature [10, 
13] (Table 1). For settings we considered community settings (i.e., home deliveries, health 
after delivery, and dispensary deliveries) assisted by SBAs, primary healthcare (PHC) 
centers, and hospitals. All WHO recommendations were assessed for appropriateness 
within each of these settings, resulting in 13 interventions eligible for inclusion (Table 2).  
The 13 interventions were then classified according to purpose (prevention, first 
response, and response to refractory PPH); setting (as above); application to vaginal 
delivery, cesarean delivery, or any type of delivery; and application during the third stage 
of labor or the first 24 hours postpartum. From a total of 38 possible combinations of the 
13 interventions that emerged from the above classification, those that included three or 
more interventions, were judged to be applicable in most settings, were intended for use 
by SKBs, and would be applicable to most women with PPH due to uterine atony were 
selected. Two recommended interventions, hemostatic surgery and arterial embolization, 
were excluded from the bundles because neither is feasible in most settings nor 
applicable to most women with PPH due to uterine atony.A
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The definition of care bundles, the criteria for selecting interventions, and the potential 
PPH care bundles were agreed upon by the experts through iterative consensus 
exercises. The process used a three-stage modified Delphi method [19], starting with two 
rounds of individual and anonymous online questionnaires with closed-ended and open-
ended questions, followed by a third round which was an in-person technical 
consultation. The first round began with questionnaire A (Supplementary File S3), which 
focused on the definition of patient care bundles and criteria to guide design of the 
bundles, followed by questionnaire B (Supplementary File S4), which asked the expert 
panel to provide relevance ratings (on a 1–9 Likert scale, where 7–9 was considered a 
“high median relevance rating”) of the individual bundles in relation to feasibility and 
implementability for three different settings. (Supplementary File S3). Each questionnaire 
underwent two rounds, the results of which provided inputs (median relevance rates and 
comments) toward consensus. Consensus was based on the ratings distribution in 
accordance with the RAND/UCLA criteria [20]. 
The experts met for an in-person consultation December 7–8, 2017, to consolidate 
agreements and to address disagreements. Presentations and discussions were held in 
plenary sessions, where the “poll everywhere” audience response system and paper 
ballots were used to record individual decisions anonymously. See Supplementary File 
S5 for details.
3 RESULTS
In the literature search, 730 articles met the initial criteria, of which 415 were excluded 
after reviews of the abstract and full text (Supplementary Figure S1). Informed by the 
literature review, the experts developed the following definition of patient care bundles, 
adapted from the IHI definition [10] with input from Lagan: “a patient care bundle is a 
limited set of evidence-based interventions for a defined patient population and care 
setting, procedure, or treatment” (from personal communication with Sally Lagan, 
National Special Projects Manager in 2003). Care bundles are meant to organize and 
simplify patient care, reinforce team performance, increase adherence to 
recommendations, and reduce variability. Some characteristics that make bundles unique A
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include their limited number of interventions [3-5], the fact that the bundle is not a 
decision-making algorithm or checklist, and the fact that measurement of compliance 
during implementation is based on the use of all interventions [10]. The definition and 
characteristics of care bundles were approved by the experts in the first online 
consultation. The systematic literature search also helped to describe different types of 
bundles and the interventions that are included in bundles, as well as to identify studies 
that describe PPH care bundles (Supplementary Tables S1 and S2).
Table 1 summarizes the 12 criteria agreed upon to assess PPH care bundles, their 
definition, median relevance rates, and the level of agreement in accordance with RAND 
relevance ratings (Supplementary File S3). The experts did not suggest additional 
criteria. There was no agreement on the relevance ratings of the following criteria: values 
and preferences, certainty of the evidence of resources, and indicator measurability due 
to divergent opinions. The other criteria received high relevance ratings (median rating 7–
9).
Three PPH care bundles that met the agreed criteria were initially identified: (1) 
prevention and recognition of PPH; (2) first response to PPH; and (3) response to 
refractory PPH. Among these three bundles, one was rejected and two were accepted. 
Prevention and recognition of PPH bundle
The bundle of interventions proposed for PPH prevention included uterotonics, controlled 
cord traction (CCT), and uterine tone assessment. In the online rounds, this bundle 
received high relevance rates and strong agreement overall (Supplementary Table S3). 
However, several issues emerged during the online rounds and were discussed at the in-
person meeting. 
The experts agreed that the proposed bundle of interventions was very similar to the 
Active Management of the Third Stage of Labor package, which in recent years has been 
de-emphasized as a care package by the WHO. One of the elements, CCT, was recently 
demonstrated to have little effect on PPH [21], and was only recommended conditionally 
in the 2012 recommendations. The expert panel agreed that bundle compliance and A
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compliance measurement would be affected by conditional application of CCT; therefore, 
a bundle should not be developed for prevention of PPH, and care should continue as 
recommended independent interventions. 
First response to PPH bundle
The set of interventions proposed for the first response to PPH care bundle included 
uterotonics, intravenous (IV) isotonic crystalloids, TXA, and uterine massage. During the 
online rounds of consultation, this bundle received high relevance rates and agreement 
from the experts for implementation at the PHC and hospital levels. However, the group 
expressed concerns that there might be barriers to implementation in many community 
settings, and the bundle might require a substantial amount of resources, such as 
equipment, supplies, training, health policies, and regulations. 
The group approved the bundle for the treatment of PPH due to uterine atony in hospitals 
and PHCs, and in the community if implemented by an SBA who was appropriately 
equipped and trained. The expert panel suggested acronyms that might be used for this 
bundle such as “MOTIVate” or “MOTIV8,” meaning massage, oxytocics, TXA, and IV 
fluids.
Response to refractory PPH bundle
The following set of interventions was proposed for the response to refractory PPH care 
bundle: continue administration of uterotonics and isotonic crystalloids, second dose of 
TXA, IBT, and non-pneumatic antishock garment (NASG). It was acknowledged that IBT 
or NASG may not be available in some settings.
During the online consultation, this bundle, intended for women who continue to bleed 
despite implementation of the first response bundle and whose condition worsens or 
deteriorates, received high RAND relevance scores, and had the agreement of the panel 
for the PHC and hospital levels. For the community level, however, the bundle received 
low RAND relevance scores for four criteria (acceptability, feasibility, indicator 
measurability, and no or minimal resources required), and there was no consensus for 
the equity criteria (Supplementary Table S3).A
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During the discussions at the in-person meeting, the following issues were discussed for 
the refractory bleeding bundle. First, uterotonics, crystalloids, and TXA were already 
included in the first response bundle, and therefore did not need to be listed as bundle 
components. Second, IBT is currently recommended by the WHO, but is considered 
controversial by some members owing to recently published evidence [22-25]. Third, in 
cases where IBT or NASG is not available, or for use during the period before IBT and 
NASG are applied, bimanual uterine compression and external aortic compression were 
suggested for bundle inclusion by some experts. Fourth, concerns were raised that 
implementing all elements of the bundle might result in the overtreatment of women with 
refractory hemorrhage whose condition was not worsening. Last, an area of contention 
was whether or not the “response to refractory PPH bundle” should be a bundle. Some 
members mentioned that the conditional, variable, and progressive changes of refractory 
hemorrhage may make this condition less appropriate for the bundle approach.
In response to these concerns, the panel considered the following points: (1) that the 
interventions from the first response bundle should be removed from the refractory 
bundle (uterotonics, crystalloids, and TXA); (2) that new evidence would continue to arise 
about all interventions in the bundles, and thus all interventions would be reconsidered by 
the WHO for inclusion in their future recommendations [26]; and (3) that the initial, 
agreed-upon assumption had been to define refractory hemorrhage as bleeding that is 
resistant to first response measures and is accompanied by worsening maternal 
condition. Some experts proposed creating a refractory PPH care package with all 
recommended interventions, but allowing for adaptation dependent on local conditions, 
as an alternative to the response to refractory PPH care bundle; however, this idea was 
not accepted by most experts. 
The panel’s final decision was to support the refractory bundle summarized in Box 1, 
comprising two manual compressive measures (aortic or bimanual uterine compression) 
and two devices, IBT and NASG, acknowledging that care providers may not implement 
the full bundle if the hemorrhage stops after one or some of the interventions. The 
primary rationale for keeping these interventions in a bundle was, first, that the “care A
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package” approach has been recommended by WHO since 2012; and second, the 
rationale for proposing a bundle approach was to improve strategies for compliance with 
best practices. 
The original aim was that the PPH bundles would apply to both vaginal and cesarean 
delivery; however, additional discussions made it clear that post-cesarean bleeding might 
require a modified approach for the following reasons: uterine massage may not be 
effective for these women; uterotonics and IV fluids are likely to be already in place, 
making these two components of the first response bundle redundant for most patients; 
and the early detection of PPH is likely to use different strategies as compared with 
vaginal delivery. Therefore, the opinion of the group was that a modified bundle that 
addresses the unique circumstances and needs of post-cesarean bleeding should be 
developed and evaluated.
The panel additionally advised that the two bundles are not meant to reflect 
comprehensive clinical care and that best clinical practices must be observed 
(Supplementary File S5). Lastly, the expert panel agreed that the bundle development 
process had focused on current WHO recommended interventions. These PPH bundles 
are “living bundles” and will be re-examined as new evidence emerges during the 
process of updating WHO recommendations and guidelines [26]. 
4 DISCUSSION 
In the present consultation, a systematic approach was used to review the care bundle 
literature to develop care bundles for atonic PPH after vaginal delivery, the elements of 
which were based on WHO-recommended PPH interventions [1, 11]. The definition of a 
patient care bundle was adapted from the IHI bundle definition as “a limited set of 
evidence-based interventions for a defined patient population and care setting, 
procedure, or treatment.” Through online and face-to-face consultations, a group of PPH 
experts came to consensus on a PPH first response bundle, consisting of uterotonics, 
isotonic crystalloid IV fluids, uterine massage, and TXA, for implementation at both the 
PHC and hospital levels. The discussion around the response to refractory PPH bundle, 
which included bimanual uterine compression, aortic compression, IBT, and NASG, in A
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addition to continuing with IV fluids, uterotonics, and TXA raised some controversy, 
although the majority of the group was in agreement about adopting it as a bundle.
The consultation process has several strengths. In the absence of a validated method for 
bundle development, a methodologically rigorous, transparent, and reproducible process 
was developed for the design of the care bundles. This process included a 
comprehensive literature review, a well-accepted and recommended list of evidence-
based interventions, a previously validated framework of criteria to guide the selection of 
WHO-recommended interventions for atonic PPH for the bundles, and a consensus 
development process among experts using the accepted modified Delphi technique.
However, there were limitations to the process. First, inherent to any consensus process 
is bias due to the influence of interpersonal dynamics. We tried to ameliorate this by 
having a diverse panel of clinical and academic experts balanced by gender, region, and 
profession, and by the anonymity of the online consultations; in addition, all members 
completed the disclosure of interest form required by WHO. Second, the process to 
modify and accept the response to refractory PPH bundle at the in-person meeting was 
different from the consensus protocol used for the online consultations. Last, since the 
publication of the 2012 WHO PPH recommendations, only one intervention has been 
updated (TXA in 2017). It is possible that new evidence may result in changes to the 
recommendations.
The two proposed PPH bundles may warrant different approaches in the next stages of 
development. The first response PPH bundle fulfills the characteristics and criteria of a 
care bundle, as articulated by the IHI. It includes four recommended interventions, 
agreed upon without exception, which should all be administered to all women with PPH 
due to uterine atony.
By contrast, the issues raised about the response to refractory PPH may merit further 
analyses and discussions. Although several publications have reported positive 
outcomes with IBTs [23-25], a randomized controlled trial reported safety concerns 
associated with implementation of a condom catheter IBT [22]. Similarly, preliminary A
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results of a stepped-wedge cluster randomized trial in Egypt, Senegal, and Uganda 
raised safety concerns associated with the implementation of an improvised a condom 
catheter IBT for treatment for unresponsive PPH (based on communication from the 
Gynuity Health Projects research team received on 2/8/2018).  To our knowledge, these 
studies are the only randomized controlled trials of improvised condom catheter IBTs 
versus no IBT. Furthermore, WHO updates on IBT recommendations will be released in 
2019. 
The panel agreed that the response to refractory PPH bundle was intended to treat 
critically ill women who continued to bleed despite first response measures and whose 
condition was worsening or deteriorating. However, this restricted definition may generate 
uncertainties for clinicians about how to treat women with refractory PPH whose condition 
remains initially stable. On the one hand, the bundle approach might be clinically less 
useful if a large proportion of women with refractory PPH are ineligible for bundle 
application. On the other hand, if all bundled interventions are given to all women with 
refractory PPH (as the bundle literature demands), there might be the potential to 
“overtreat” some women. It is acknowledged that many care providers will stop 
implementing other bundle components if the initial intervention works; however, that 
approach, even if clinically logical, would contradict the accepted definition of a “care 
bundle,” in which all interventions should be administered. If not all interventions are 
administered, the response to refractory PPH “bundle” would be more similar to a care 
package, where a clinical algorithm is used to define which interventions to apply and 
when to stop [28]. Many of the experts were more concerned about undertreatment and 
delayed recognition of PPH than about the risk of overtreatment of women with severe 
refractory PPH. Experts raised the issue of the impossibility of a single front-line worker 
being able to perform all of the bundle interventions if they were applying either of the 
manual compression measures. In addition, some experts stated that it was possible that 
the clinical conditions of women experiencing refractory PPH might be too variable, 
progressive, and conditional, thereby requiring an incremental, more tailored, 
individualized approach rather than a care bundle approach.
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The development and implementation of the bundles should not prevent care providers 
from making a thorough assessment of the etiology of PPH before intervening. We note 
that, although both TXA and the NASG can be effective for non-atonic obstetric 
hemorrhage etiologies, these bundles are recommended for uterine atony. Although the 
proposed care bundles are based on rigorously developed evidence-based 
recommendations, they have yet to be tested and evaluated as a strategy to improve 
clinical care for PPH.
For the first response PPH bundle, the next phase is the development of an 
implementation strategy, culminating in a model for use at the facility level in LMICs. This 
strategy must include training on use of the bundles; support for health systems’ 
processes of communication, teamwork, and cooperation; packaging bundles with non-
commodity components; and supportive supervision, monitoring, and evaluation.
For the response to refractory PPH bundle, it is a priority to solve pending controversies 
including the operational definition of refractory PPH, and to better understand the 
effectiveness of various IBT devices. For any PPH bundle, strengthening commodity 
supply chains and encouraging behavior change are critical to implementation. 
Assessment of facilitators and barriers should guide the development of the strategy. The 
approach will need to be tailored to local contexts to ensure sustainability. Similarly, 
leadership from ministries and key stakeholders will be critical for successful bundle 
implementation. We expect that the PPH bundles will reduce rates of severe PPH, 
morbidity, and mortality, through improved quality of care and adherence to global, high-
quality guidelines; however, this has not yet been demonstrated. Future research must 
rigorously assess how these bundles are implemented in practice, including the 
mechanisms of impact and how these are influenced by the context [29]. Factors to be 
evaluated include bundle feasibility, acceptability, safety, adverse consequences, and 
effectiveness relative to individual interventions. The opinions of healthcare planners, 
practitioners, and users will be important to consider. Cost-effectiveness and impact 
should be studied at both the hospital and PHC levels to evaluate the value of the 
bundles in different settings and relative to other strategies, which might better improve 
use of recommended individual interventions. Although both bundles are suitable for use A
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in PHCs, early adoption and ownership at the referral hospitals in their catchment area 
will build support for introduction into PHCs; therefore, an incremental introduction may 
be necessary. Because the expert panel developed PPH bundles for facility-level 
implementation, other strategies may need to be developed for deliveries taking place at 
the community level. There also may need to be consideration of what bundle elements 
may be implemented if there is only one provider (with one pair of hands).
Given these considerations, there will be a need for implementation research to 
determine if the bundling approach will ultimately make a difference in saving women’s 
lives from PPH.
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FIGURE LEGENDS
Figure 1 Flowchart of phases and procedures performed for development of PPH care 
bundles during the technical consultation.
SUPPORTING MATERIALS LEGENDS
Supplementary Box S1 Examples of best clinical practices.A
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Supplementary Table S1 Type of bundles and interventions based on the systematic 
search of the literature.
Supplementary Table S2 Main characteristics of the maternal and PPH studies 
reviewed.
Supplementary Table S3 Performance of each bundle for the five feasibility criteria 
assessed at the three individual settings.
Supplementary File S1 Technical consultation participants.
Supplementary File S2 Methodologic details.
Supplementary File S3 Survey 1.
Supplementary File S4 Survey 2.
Supplementary File S5 Technical consultation agenda.
Supplementary Figure S1 Flowchart of the systematic search of the literature.
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Table 1 Panel rating and agreement on the criteria used to assess the PPH care bundle.
Order 
no.
Criterion Description Rating a Agreement b
1 Desirable effects
How substantial are the desirable anticipated effects of the intervention? Judgments about how 
substantial the effects are should take into account the absolute magnitude of the effect (e.g., the 
proportion of individuals who would benefit) and the importance of the outcome (how much it is 
valued by the affected individuals). 
8.5 (8–9) Yes
2 Undesirable effects
How substantial are the undesirable anticipated effects of the intervention? Judgments about how 
substantial the undesirable effects are should take into account the absolute magnitude of the effect 
(e.g., the proportion of individuals who would benefit) and the importance of the outcome (how much 
it is valued by the affected individuals). 
8 (7–8.5) Yes
3
Certainty of the 
evidence on the 
effects
What is the overall certainty (also called quality) of the evidence of the intervention’s effects? In the 
context of making decisions, the certainty rating reflects the extent of our confidence that the estimate 
of an effect (including test accuracy and associations) is adequate to support a particular selection. 
8.5 (7.5–9)Yes
4
Values and 
preferences
Is there significant uncertainty about, or variability in, how much women value the outcomes 
associated with the intervention? Uncertainty about how much those affected (patients or their carers) 
value the outcomes of interest can be a reason for not selecting an intervention. Variability in how 
patients value the main outcomes (to the extent that individuals with different values would make 
different decisions) is another reason for not selecting an intervention.
7 (4.5–7) No
5 Balance of effects
Does the balance between desirable and undesirable effects favor the intervention? Judgments about 
the balance between the desirable and undesirable effects need to take into account the preceding 
four criteria: the magnitude of the desirable and undesirable effects, the certainty of the evidence 
supporting the anticipated effects, and how much those who are affected value the outcomes.
8 (7–8.5) Yes
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6
Certainty of the 
evidence on resources 
required
What is the certainty of the evidence for the costs of the intervention? If resource use is considered 
critical for a recommendation, the less certain the evidence for resource requirements, the less likely 
it is that a panel should select or not the intervention. 
6 (4–7.5) No
7 Cost-effectiveness
Judgments about the cost effectiveness of an intervention need to take into account several criteria 
including the balance between the desirable and undesirable effects (the net benefit); the certainty of 
the evidence of effects and uncertainty about or variability in how much individuals value the main 
outcomes; and resource requirements (cost) and uncertainty about the costs.
7.5 (7–8) Yes
8 Resources required
How large are the resource requirements (costs in terms of both money and time) of the bundle? The 
greater the cost, the less likely it is that a bundle will be selected.
8 (7.5–9) Yes
9 Equity
What would be the impact of the bundle on health equity? This criterion evaluates if a bundle is 
expected to reduce health inequities. It considers whether a bundle will reduce differences in the 
effectiveness for disadvantaged populations within countries, such as low-income groups, less 
educated individuals, and/or rural populations.
8 (6.5–9) Yes
10 Acceptability
Is the bundle acceptable to key stakeholders (women and providers)? A bundle might vary on its 
acceptability level due to ethical principles (e.g., autonomy, beneficence or justice), as well as the 
distribution of the desirable and undesirable effects and costs (who benefits or is harmed, and who 
pays or saves). 
8 (6.5–9) Yes
11 Feasibility 
Is the bundle feasible to implement? Feasibility is influenced by factors such as the resources 
available, infrastructure, and training. If the bundle elements are not already in use, this criterion 
evaluates if the bundle can be introduced with a reasonable investment of cost, time, and training. 
Clinicians might find a care bundle unhelpful if the included interventions are not implementable in 
their settings. 
8 (7–8) Yes
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12 Indicator measurability
This criterion evaluates whether an indicator for the intervention’s use is available and can be simply 
and reliably measured during routine clinical practice, without or with a minimum of extra resources. 
Indicators are quantitative or qualitative factors or variables that provide a simple and reliable means 
to measure achievement.
5 (5–7) No
a Values are given as median (interquartile range).
b Agreement was defined with as a disagreement index of <1.
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Table 2 Description of WHO-recommended clinical interventions for PPH, 2012–2017.
Intervention Description
Uterotonics Administration of oxytocin (IV/IM); ergometrine/methylergometrine or other fixed drug combination of oxytocin and 
ergometrine(IM); misoprostol (oral). 
The preferred drug for prevention of PPH is oxytocin (10 IU, IV/IM). If unavailable, give IM ergometrine/methylergometrine or 
the fixed drug combination of oxytocin and ergometrine, if not contraindicated. If IM or IV uterotonics are unavailable, give oral 
misoprostol (600 g).
Controlled cord traction After delivery of the newborn and it is assessed that there are no other fetuses in utero, gentle traction is applied to the 
umbilical cord with one hand, while the other hand applies abdominal counter-pressure on the uterus.
Postpartum abdominal 
uterine tonus assessment 
Palpate the uterus to assess uterine firmness/tone; if the uterus is soft or flabby this many indicate uterine atony.
Isotonic crystalloids Administration of a starting dose: 500 mL of isotonic crystalloids IV, in 30 min; and continuing doses of 500 mL of isotonic 
crystalloids IV, in 60 min.
TXA A fixed dose of 1 g of TXA (100 mg/mL IV at 1 mL per min), within 3 h of the time of diagnosis (if unknown, time of delivery); a 
second dose of 1 g can be given if needed 30 minutes after the first dose.
Uterine massage Circular rubbing of the uterus achieved via manual massaging of the abdomen. This is typically sustained until the bleeding 
stops or the uterus contracts.
Intrauterine balloon 
tamponade 
The procedure entails insertion of a deflated/uninflated balloon into the uterine cavity and then inflating it to achieve a 
tamponade effect.
Bimanual uterine 
compression
Two handed, one in the anterior vaginal fornix and one behind the uterine fundus, squeezing the uterus between the hands.
External aortic 
compression
External compression applied with a closed fist at the level of the umbilicus and slightly to the woman’s left 
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NASG Used as a temporizing measure until source of bleeding found and treated. NASG is a lower body compression device made 
of stretch neoprene which closes tightly with Velcro in segments for the ankles, calves, thighs, pelvis, and abdomen and is 
applied rapidly starting at the ankles.
A single dose of antibiotics In the context of placental retention, the placenta should be extracted, and a single dose of antibiotics administered.
Uterine artery embolizationIf other measures have failed and if the necessary resources are available, the use of uterine artery embolization is 
recommended as a treatment for PPH due to uterine atony.
Surgical intervention If bleeding persists despite treatment with uterotonic drugs and other conservative interventions, surgical intervention should 
be used without further delay.
Abbreviations: IM, intramuscular; IV, intravenous; NASG, non-pneumatic antishock garment; PPH, postpartum hemorrhage; TXA, tranexamic acid.
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Box 1 Final care bundles for postpartum hemorrhage.
First response PPH bundle
Uterotonic drugs
Isotonic crystalloids
Tranexamic acid 
Uterine massage
Notes: Initial fluid resuscitation is performed together with intravenous (IV) administration of 
uterotonics. If IV uterotonics are not available, fluid resuscitation should be started in parallel with 
sublingual misoprostol or other parenteral uterotonics. If postpartum hemorrhage (PPH) is in the 
context of placental retention, the placenta should be extracted and a single dose of antibiotics 
should be administered.
Response to refractory PPH bundle
Compressive measure (aortic compression or bimanual uterine compression)
Intrauterine balloon tamponade
Non-pneumatic anti shock garment
Notes: A continuing dose of uterotonics (e.g., oxytocin diluted in isotonic crystalloids) and a second 
dose of tranexamic acid should be administered during the application of this bundle.
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Proposal of care bundle definition and essential characteristics 
based on bundles’ literature 
Assessment of care bundle definition and criteria to select interventions 
 
• Delphi round 1 (online) questionnaire A 
• 2 iterations  
Creation of 38 potential care bundles from 
WHO recommended interventions 
3 potential bundles proposed 
PPH prevention bundle 
eliminated 
PPH first response bundle 
approved 
Development and pilot of questionnaire A 
Assessment of potential bundles 
considering applicability of characteristics 
at the bundle levelb 
Development and pilot of questionnaire B to assess bundles 
feasibility and implementabilityc 
Establishment of a steering group and technical advisory group  
Selection of interventions to be included in the bundles 
Assessment of proposed PPH care bundles for three settings: community, PHC and hospitals 
 
• Delphi round 2 (online) questionnaire B 
• 2 iterations 
• to address disagreements with feedback on previous round 
• Delphi round 3 (in-person) 
• Presentation of previous results and comments 
• Discussion of disagreements 
• Final voting 
Summary of round 1 and 2 results 
Response to refractory PPH bundle  
approved 
Proposal of a list of criteria for interventions’ selection         
(11 from EtDa  and 1 from the bundles’ literature)  
Final Consensus 
a GRADE Evidence to Decision frameworks (EtD), developed as part of the DECIDE project 
b Characteristics considered by the steering group at the bundle level: sets that included three or more interventions, that are applicable in most 
settings, to the majority of women giving birth and PPH cases, and births attended by skilled births attendants. 
c Resources Required, Equity, Acceptability, Feasibility and Indicator Measurability  
Literature search 
ijgo_13028_f1.pptx
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